Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Phio Pharmaceuticals Corp. (PHIO)

Compare

1.2100

-0.0200

(-1.63%)

At close: 4:00:00 PM EDT

1.2212

+0.01

+(0.93%)

After hours: 5:16:41 PM EDT

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - March 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today reported its financial results for the year

Newsfile 2 days ago

PHIO
-1.63%
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced that a podium presentation addressing its lead product candidate, P

Newsfile 23 days ago

PHIO
-1.63%
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it has fulfilled the required enrollment for safety in its third dose cohort in its Phase 1b dose escalating clinical study for their lead compound PH-762. The company

Newsfile 28 days ago

PHIO
-1.63%
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Registration Link for Presentation and live Q&A to take place, Wednesday March 5, 2025 at 12:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharma

Newsfile last month

PHIO
-1.63%
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Co

Newsfile last month

PHIO
-1.63%
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Registration Link for Presentation and live Q&A to take place, Wednesday January 29, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Ph

Newsfile 2 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs to be incurred in connection with PH-762 clinical activitiesMarlborough, Massachusetts--(Newsfile Corp. - January 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells,

Newsfile 2 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 610,000 shares of its common stock at a purchase price of $3.00 per share in a registered ...

Newsfile 2 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 833,335 shares of its common stock at a purchase price of $3.00 per share in a registered ...

Newsfile 2 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,063,670 shares of its common stock at a purchase price of $3.00 per share in a registered ..

Newsfile 2 months ago

PHIO
-1.63%
Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

On Monday, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from Benzinga Pro. Phio reported pathologic responses for patients enrolled in the 2nd cohort, which includes two patients with a complete response or 100% tumor clearance. Phio’s ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2

Benzinga 2 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2

Newsfile 2 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

INTASYL Compound RXI-231: a promising approach to treatment of hyperpigmentation Marlborough, Massachusetts--(Newsfile Corp. - January 2, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the publication of research entitled, Self-delivering RNAi Compounds for Reduction of Hype

Newsfile 2 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 240,000 shares of its common stock at a purchase price of $2.00 per share in a registered ...

Newsfile 3 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 437,192 shares of its common stock at a purchase price of $2.635 per share in a registered ..

Newsfile 3 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Phio's Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells. Phio announced today that the Safety Monitoring Committee

Newsfile 3 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Journal is the official publication of the International Union of Immunological Societies Marlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells announced today its manuscript, Self-delivering RNAi Immunotherapeutic PH-762 Silences PD-1 to Genera

Newsfile 3 months ago

PHIO
-1.63%
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Award is being presented during Advanced Therapies Week 2025 in Dallas Marlborough, Massachusetts--(Newsfile Corp. - December 10, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced the company is a finalist for the Technology Disruptor of the Year. The awards are part of Advan

Newsfile 3 months ago

PHIO
-1.63%
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a cancer-free future, today announced it has completed the enrollment of its second patient cohort in its PH-762 Phase 1b dose-escalating clinical trial, and added a sixth clinical site in San Diego, CA. Phio recently presented new data from the ongoing ...

Newsfile 4 months ago

PHIO
-1.63%
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells today reported its financial results for the quarter ended September 30, 2024 and provided a business update.Recent Corporate UpdatesThe Phase 1b dose escalation c

Newsfile 4 months ago

PHIO
-1.63%

Performance Overview

Return	PHIO	S&P 500 (^GSPC)
YTD	-32.78%	-3.58%
1-Year	-79.93%	+8.94%
3-Year	-98.72%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Phio Pharmaceuticals Corp. (PHIO)

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Performance Overview